CCR5
C-C chemokine receptor type 5
As of the edition of 20 October 2026, CCR5 (C-C chemokine receptor type 5, UniProt P51681) has 13 drugs tested at it and 10 companies on the list, 8 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P51681
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 26
- Disease areas
- Infections; Immune system; Urinary and reproductive; Digestive system; Cancer; Lungs and airways; Skin and connective tissue; Nervous system
- Registered trials of its drugs
- 203
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 5 |
| Stopped | 6 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Maraviroc | Marketed | Phase 4 | none listed |
| Leronlimab | Active | Phase 3 | none listed |
| Cenicriviroc | Stopped | Phase 3 | none listed |
| Vicriviroc | Went quiet | Phase 3 | none listed |
| AZD5672 | Went quiet | Phase 2 | none listed |
| Aplaviroc | Stopped | Phase 3 | none listed |
| BMS-813160 | Stopped | Phase 2 | none listed |
| GSK706769 | Stopped | Phase 2 | none listed |
| PF-04634817 | Stopped | Phase 2 | none listed |
| CCR5MAB004 | Went quiet | Phase 1 | none listed |
| HGS-1025 | Stopped | Phase 1 | none listed |
| INCB-9471 | Went quiet | Phase 2 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Route B | 1 |
| Engaged | 1 |
| Total on the list | 10 |
The other 7 companies at CCR5
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at CCR5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.